elranatamab-bcmm

{
  "id": "MLC-T-ONC-013311",
  "term": "elranatamab-bcmm",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab-bcmm binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.",
  "synonyms": [
    "elranatamab",
    "anti-CD3/anti-BCMA bispecific antibody PF-06863135",
    "BCMA x CD3 bispecific antibody PF-06863135",
    "BCMA-CD3 bispecific Ab PF-06863135",
    "B-cell maturation antigen-CD3 bispecific antibody PF-06863135"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/elranatamab-bcmm/"
}